Pulsed radiofrequency is a growingly popular pain treatment modality. However, its clinical efficacy remains controversial. In this review, the available literature on pulsed radiofrequency is critically analysed to determine its clinical efficacy. Our search of the literature for pulsed radiofrequency yielded 341 citations; after reviewing the abstracts we found 51 relevant articles. There were 4 review articles: 44 articles pertained to the application of pulsed radiofrequency by an electrode placed in the vicinity of a neural structure. Of these only two were randomised controlled trials. Of the remaining 42 articles, one was a non-randomised controlled trial, three were prospective uncontrolled trials: there were six retrospective studies, 11 case reports, eight laboratory studies, two position papers, five editorials and seven items of correspondence, while one publication reported two studies. Three articles pertained to transcutaneous application of pulsed radiofrequency. Of the two randomised controlled trials, one reported efficacy of the pulsed radiofrequency while the other reported it to be ineffective. The majority of the uncontrolled and observational studies reported clinical efficacy of pulsed radiofrequency, however many of these studies had limitations. Further randomised controlled clinical trials are recommended in order for the practising pain physician to clearly understand the role of pulsed radiofrequency in the treatment of various chronic pain syndromes.
Pulsed radiofrequency (PRF) has been used for the treatment of various pain syndromes for well over a decade and its popularity has increased significantly in recent years. The growing popularity of PRF is most likely due to its apparent lack of side-effects and its perceived clinical efficacy; an impression often generated after a cursory review of the literature available on this topic. It is well known however, that the quality of published literature can vary considerably and it is not uncommon for therapies with uncertain efficacies to become established before being rigorously tested 1 . The four previous review articles 2-5 on this topic provided data that are mostly uncontrolled and observational. Our goal in this review is to comprehensively analyse the available literature on PRF, including the newly available randomised controlled trials (RCTs), and to give the practising pain physician a clearer understanding of the current knowledge of its biological basis and its clinical efficacy.
METHODS
We searched MEDLINE, EMBASE and Cochrane databases for key words "pulsed radiofrequency" and "pulsed radio frequency", applying no limits and in all languages. Our search yielded 341 articles; after reviewing the abstracts we found 51 articles that pertained to the applications of pulsed mode of radiofrequency (RF) currents for the treatment of various pain syndromes . There were four review articles 2-5 : 44 articles pertained to the application of pulsed mode of RF by an electrode placed in the vicinity of a target neural structure using the typical PRF protocol (RF pulses applied for 20 milliseconds, at 2 Hz, for 120 seconds, with maximum tissue temperatures of 42°C), referred to here as PRF. Two articles described its application in the form of a discharge beam applied transcutaneously thorough intact skin (TC-PRF) [50] [51] and one described its application transcutaneously via transcutaneous electrical nerve stimulation (TENS) electrodes 52 . Although other data in the form of pain conference abstracts are available on this topic, we have limited our review to peer-reviewed literature published in scientific journals.
We encountered 24 clinical studies 51, 52 , which included three RCTs 6, 7, 51 , one non-randomised controlled trial 8 , three prospective uncontrolled trials [8] [9] [10] , six retrospective studies [11] [12] [13] [14] [15] [16] and 12 case series or case reports [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 52 (one publication reported on two trials 8 ). We encountered nine basic science studies [28] [29] [30] [31] [32] [33] [34] [35] 50 , of which there were six animal studies [28] [29] [30] [31] [32] 50 and three in vitro studies [33] [34] [35] . There were two position papers 36, 37 , five editorials [38] [39] [40] [41] [42] and seven items of correspondence [43] [44] [45] [46] [47] [48] [49] . Nine clinical studies described the application of PRF to the dorsal root ganglia (DRG) 6, 8, 9, 13, 14, [17] [18] [19] [20] , eight to the peripheral nerves [11] [12] [13] 17, [21] [22] [23] [24] , including two to medial branches of the dorsal rami 11, 12 . Two studies described PRF application to the trigeminal ganglion 7, 25 , two to the sphenopalatine ganglion 15, 26 and one each to the intervertebral disc 16 , sacroiliac joint 10 and glossopharyngeal nerve 27 . There were two clinical studies that applied PRF to more then one target 13, 17 .
RESULTS

Prospective controlled trials
Sluijter et al 8 in 1998 published the first report on PRF, which included a prospective controlled trial of 60 patients with unilateral radicular pain: 36 patients received PRF of the involved DRG, while 24 received conventional thermal radiofrequency (also referred to as continuous radiofrequency or CRF), with a maximum temperature of 42°C. At six weeks, using Global Perceived Effect (GPE) as the outcome measure, 56% of the patients who received PRF reported >75% improvement, while only one patient (4%) in the CRF at 42°C group reported similar GPE scores. The authors concluded that the PRF was superior to the CRF at 42°C in the treatment of radicular pain. Although prospective, this trial was not randomised, it used no pain scales, the patients were monitored for shortterm only (six weeks) and it compared PRF to a form of thermal RF (CRF at 42°C) not used in routine clinical practice.
We found only two RCTs of PRF application 6,7 . The first trial was of 23 patients with cervical radicular syndrome 6 ; 11 patients received PRF while 12 had sham treatment of the involved DRG. At three months, patients in the PRF group had significantly better results, >50% improvement in GPE scores and 20 point reduction in visual analogue scale (VAS) scores. This study was a randomised sham-controlled and blinded trial: however, due to the slow inclusion rate, the number of patients studied (23 patients) was well short of the intended target (42 patients), making the study results statistically less powerful. The characteristics of the study groups were also dissimilar and patients in the sham treated group had significantly higher pre-treatment VAS scores (76.2 vs. 55.7).
In addition, only short-termed results (three months) were reported. The second RCT of PRF 7 included 40 patients with idiopathic trigeminal neuralgia (TN). Patients in two equal groups (20 patients each) randomly received either the PRF or CRF at 70°C, of the involved trigeminal ganglion. One day after the procedure, patients in the CRF at 70°C group had significant decrease in the mean VAS (mVAS) scores (mVAS reduced from 9 to 1) and improvement in the patient satisfaction scale (PSS) scores; this improvement continued at six months (mVAS of 0.5). Only two of the 20 patients in the PRF group showed pain relief at first postprocedure day and the mVAS in the remaining patients reduced minimally (from 9 to 8); at three months all patients in the PRF group had intractable pain. Patients in PRF group were treated by CRF at 70°C at three months and they experienced pain relief similar to the CRF at 70°C group; mVAS reduced from 8 to 1 at day one and had mVAS of 1 at six months. The authors of this study concluded that compared to CRF, PRF was an ineffective treatment for TN. This trial was also a randomised, controlled and blinded trial and the two study groups had comparable demographics. However, in this trial also the follow-up period was limited to six months and the study lacked a placebo control group. The success rate reported for the CRF (almost 100%) is also disproportionately higher than that observed historically for this method of treatment in patients with TN 53 . We found only one clinical study of TC-PRF 51 . This study was a prospective, randomised and sham-controlled trial of 40 patients with temporomandibular arthralgia (TMA). TC-PRF was applied to the effected joint at alternate days for two weeks. For four weeks after the treatments, patients treated with TC-PRF showed mean numerical rating scale (NRS) score reduction of 3.07 points vs. 1.15 point pain reduction for patients in the control group. Although TC-PRF was found to be an effective treatment for TMA, a significant effect for the controls was also observed. In this study the aetiology of TMA was not elucidated, making it likely that the study population was non-homogeneous. Despite the fact that the treatments were applied over the course of two weeks, the pain relief was reported for only 26 days and neither the target nor the mechanism of action of this method of pain relief was obvious.
Prospective uncontrolled trials
We found two prospective studies of PRF-DRG. The first publication on PRF by Sluijter et al 8 also reported on 20 post-spine surgery patients with six-month history of unilateral lumbar radicular pain. Five of these patients did not experience pain relief after the diagnostic blocks and were excluded from the study and the remaining 15 patients received PRF of the suspected DRG. At six months, eight of the 15 patients had satisfactory results, with decrease in the mVAS scores of 3.5 and improvement in the Oswestry disability scores of 28.3. Two of the eight patients reported return of their pain after six months, while the remaining six patients continued to experience pain relief at 12 months. In this report on 20 patients, pain relief was observed in only six patients at one year (30%). The second prospective uncontrolled study 9 was of 28 patients with chronic neuropathic spinal pain, who received PRF of the suspected DRG. No diagnostic blocks were performed and the treatment level was determined solely by clinical and imaging findings. At three months, 82% of the patients reported improvement in their VAS scores; a trend that continued at one year (68%). All the patients had concurrent treatments that included injection of methylprednisolone 80 mg prior to the PRF application and oral anti-inflammatory medications and physical therapy for one month after the procedure. In addition to the lack of diagnostic blocks and concurrent treatments, the nature and aetiology of the spinal neuropathic pain was not elucidated.
We found only one study of PRF application for sacroiliac joint (SIJ) pain 10 . In this prospective study, 22 patients who responded temporarily to a minimum of two local anaesthetic and steroid injections to the affected SIJ received PRF of the medial branches of L4 and L5 and the lateral branches of S1 and S2. At six months, using VAS and Functional Assessment of Chronic Illness Therapy (FACIT) scores, success was reported in 72% of the patients with mean duration of pain relief of 20 weeks. The total number of blocks performed in a patient was not clarified and it is unclear if the blocks performed were primarily diagnostic or therapeutic in nature. In addition, the study lacked any details of the techniques used and the outcome data was collected inconsistently.
Retrospective studies
We found two retrospective studies of PRF application for facet syndrome. The study by Mikeladze et al 11 reported data from 114 patients with back and neck facet joint syndrome. PRF was applied to the medial branch of the dorsal rami and successful pain relief (VAS reduction of >50%, for >1.5 months) was observed in 68 patients (59.6%) for an average of 3.93 +/-1.86 months. Although this study reported on a relatively large number of patients, the criteria described for the success were modest (>50% reduction of pain) and the pain relief achieved was for short-term only; features also seen after nonspecific facet joint interventions and can be attributed to a placebo response 54 . In the second retrospective review 12 of 71 patients, who received PRF of the medial branches for facet syndrome, 23 patients were excluded for a variety reasons. Of the remaining 48 patients, 26 reported improvement in their NRS scores for up to four 13 published retrospective data on 49 patients with chronic postsurgical thoracic pain. Twenty-eight patients who received PRF of either the intercostal nerves (n-15) or the DRG (n-13) were compared to the patients treated pharmacologically (n-21). At six weeks, 62% of the patients who received PRF of the DRG reported ≥50% pain relief compared to 21% in the intercostal PRF group and 27% in the medically managed group, a trend towards better outcome in the DRG group, which continued at three months. This study reported on patients with multiple aetiologies of their postsurgical thoracic pain, it used non-homogeneous pharmacologic management and applied non-standardised pain assessment tools. In the second study 14 , 13 patients with history of lumbar radicular pains due to herniated disc, and who were deemed candidates for surgery, received PRF of the suspected DRG at one or more levels. Nine of these patients in addition had motor and sensory deficits of the involved dermatomes. Significant improvement in the NRS scores (>5 points) was reported in all but one patient at one year and surgery was avoided in these patients. Resolution of the neurological deficits was reported in all the patients with neurological manifestations. The authors recommended PRF-DRG for the treatment of herniated intervertebral disc as an alternative to epidural steroid injections, even though no direct comparison was made between the two treatments. No diagnostic blocks were performed in this study and the level of DRG treated was based entirely on clinical and imaging findings. The criterion for patients selected for the study was candidacy for surgery; the criteria for this candidacy however were not elucidated. Also, the mechanism of resolution of neurological deficits appears different from its usually suggested neuromodulatory role.
There is one retrospective study of PRF application for chronic head and facial pain. Bayer et al 15 reported retrospectively on the results of PRF application to the sphenopalatine ganglion for chronic head and facial pain of diverse aetiology. Of the 46 patients originally included in the study, data was reported from 30 patients since 16 patients were lost to the follow-up. At follow-up, which varied from four to 52 months, 65% of the patients reported mild to moderate pain relief, while 21% had complete pain relief. In this study, 87% of the patients received concurrent treatments that included medical and/or surgical therapy, the study population was non-homogeneous and the follow-up period varied considerably and had a high attrition rate.
There is one retrospective study of unusual application of PRF; in this study PRF was applied intradiscally using unconventional parameters 16 . Eight patients with chronic discogenic low back pain, confirmed by diagnostic discography, received intra-discal PRF. A long 20 gauge electrode with 15 mm active tip was placed inside the suspected disc and PRF was applied for 20 minutes. At three months, all eight patients reported significant reduction in their NRS scores (4 points). Longer-term follow-up, varying between six and 25 months, was available for five of the eight patients and these patients continued to report good pain relief (four patients were pain free while one had NRS score of 2). The follow-up period in this study varied from six to 25 months and was not available for 37% (three of the eight patients) of the patients studied. The 100% success rate of PRF, in an unconventional application, necessitates the performance of similar studies with a control group.
Case reports and case series
We found 12 case reports or case series of the use of pulsed mode of RF application, 11 of PRF [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] and one of transcutaneous pulsed RF via TENS electrodes 52 . PRF was applied to the DRG in four reports [17] [18] [19] [20] , which included cervical, thoracic and lumbar levels. We encountered five reports of PRF application to the peripheral nerves 17,21-24 , including intercostal, inguinal, suprascapular and occipital nerves. There was one report each of PRF application to Gasserian ganglion 25 , sphenopalatine ganglion 26 and glossopharyngeal nerve 27 . Marked improvement in pain and function with PRF application was reported in almost all of these reports. However, the chronicity of pain symptoms, short-term results, liberal criteria used for success and the use of PRF as a last resort, in many of these reports, make placebo response a distinct possibility in some of the reported successes.
Laboratory studies
Three studies measured markers of cell stress after PRF application. The study by Higuchi et al 28 was the first basic science study conducted to explain the proposed clinical effects of PRF. In a rat model, PRF was applied to the DRG and three hours later, significant increase in the number of gene c-fos immunoreactive neurons was observed in the superficial laminae of the dorsal spinal horns. A similar increase in c-fos was not observed in sham treated animals or in animals that received CRF at 38°C. The authors theorised that the higher voltages applied periodically during PRF delivered much higher levels of electromagnetic force (EMF) than the lower voltages applied continuously during low temperature CRF, rendering the latter (CRF at 38°C) ineffective. The authors of this study concluded that factors other than temperature, i.e. EMF, were responsible for this neuronal activation. The significance of this short-term (three hours) neuronal activation in response to the PRF of DRG is however unclear; the presence of c-fos indicates neural activation and its presence at three hours does not equate with long-term nociception 55 . In another similarly study in rats 29 , increases in c-fos immunoreactive cells were shown at seven days and a long-term effect of PRF on neuronal activation was proposed. In this study, equal efficacy was shown for PRF and CRF at 67°C when compared to sham-operated animals. It is interesting to note however that no lower temperature (38 or 42°C) CRF group was included in this study and the effects of PRF were not compared to CRF at comparable temperatures.
Also using a rat model, Hamann et al 30 applied PRF to either the sciatic nerve or the proximity of DRG (the L4 anterior ramus) and measured Activating Transcription Factor-3 (ATF-3) in the DRG, a marker of cellular stress 56 . The study also included a sham-treated group and an axotomy group (the L4 anterior primary ramus was transected). No increase in ATF-3 positive neurons was found in the sham-operated animals or when the PRF was applied distally along the sciatic nerve, a moderate increase was found when the PRF was applied in the vicinity of the DRG and a marked increase was observed after the transaction of anterior primary ramus. The authors of this study concluded that PRF caused cell stress without an overt thermal injury: however, they did not rule out the possibility that individual PRF pulses might generate enough heat to cause this cell stress. The mechanism of neuronal stimulation in this study is therefore unclear (heat vs. EMF) and, like the c-fos studies, the significance of ATF-3 release and neuronal stimulation in response to PRF application remains unclear. Two studies compared the morphological changes in the tissues in response to application of various modes of RF energy. In the first study, rabbit DRGs were exposed to PRF, CRF at 67°C, a sham treated group (electrode placement on the DRGs but no RF applied) and a control group (no intervention) 31 . At two weeks there was no difference in the light microscopic appearances of DRGs in all of the above groups and the electron microscopic appearance showed no pathological findings in the DRGs of the sham-operated and the control groups. The electron microscopic appearance of the DRGs in both the CRF at 67°C and the PRF groups however, showed damage to the cellular substructure that was greater in the CRF at 67°C group. The authors concluded that PRF was substantially less destructive than CRF at 67°C. Interestingly, this study only compared PRF to CRF at 67°C and such cellular changes are expected at these temperatures 57 .
In the second study, various RF and heat modalities were applied to the DRG and sciatic nerve in a rat model 32 . The study groups included PRF, CRF at 42°C, CRF at 80°C, conductive heat probe at 42°C and a sham-treated group (electrode placed but no RF current applied). Light microscopic observations made at two, seven and 21 days showed that the method of heating to 42°C caused no difference in tissue pathology; each produced oedema at two days that persisted through seven days and was resolved by 21 days. In contrast, lesions at 80°C consistently created thermal lesions characterised by Wallerian degeneration and no PRF did not depend in the thermal effects and had a neuromodulatory role.
Cosman and Cosman 34
Mathematical calculations correlated with data from liver and egg white model.
Electrical potentials and heat, both capable of destructive effects during PRF.
PRF produced its effects by heat and electrical currents.
Heavner et al 35 Egg whites exposed to PRF at 42, 60, 65, and 70°C and to CRF at 80°C.
No coagulation with PRF at 42°C. Coagulation just visible at PRF at 60°C and similar to CRF at 80°C.
Thermocoagulation was a function of set temperature and did not depend on the method of RF application.
PRF=pulsed radiofrequency, DRG=dorsal root ganglion, CRF=continuous radiofrequency pathological change was evident in the sham-treated group. These observations suggested that the low-grade thermal injury was mainly responsible for the observed tissue morphology and any effects of EMF on the cell morphology were not evident. Three studies used in vitro models to explain the effects of PRF. Using preparations of rat neuronal tissue, Cahana et al 33 measured postsynaptic neuronal potentials and effects on tissue architecture, in response to various RF modalities. Compared to CRF at 42°C, PRF at 38°C and at 42°C produced only a transient reduction of postsynaptic neuronal potentials and was significantly less destructive; even though the voltage applied and thus the EMF delivered during the CRF was considerably lower than that used during PRF (1.5 mA vs. 50 mA). These authors concluded that PRF did not depend on its thermal effects for its anti-nociceptive properties and that it had a neuromodulatory role. This study demonstrated that despite generating lower EMF, CRF at 42°C had more in vitro effects and caused more tissue injury than PRF at similar temperature. These observations therefore contradicted the mechanism of PRF effect proposed by earlier investigators, i.e. PRF caused cellular dysfunction by higher EMF and that CRF at 42°C was ineffective 8 .
Cosman and Cosman et al 34 used mathematical equations and tissue models to calculate the thermal and electromagnetic effects of RF waves. Their calculations showed that PRF was capable of generating levels of thermal energy and electrical currents capable of cellular injury and suggested a combined role of electrical currents and thermal energy for PRF effect; a shift from the original EMF paradigm.
Heavner et al 35 compared the abilities of various modalities of RF to coagulate the egg whites and compared the effects of PRF at 42°C, 60°C, 65°C and 70°C to CRF at 80°C. Their results showed that the coagulation of egg whites occurred once the temperature was above 60°C and was irrespective of the method of RF application. They concluded that thermocoagulation was predominantly a function of set temperature. Although this study undermined the significance of pulsatile mode of RF application, it did not compare PRF to comparable lower temperature CRF (CRF at 42°C) and thus the effect of lower temperature CRF on egg white was not elucidated.
Side-effects and complications of PRF
Although a potential for bleeding, infection, nerve damage from needle placement, post procedure neuritis and burns from incorrect placement of the grounding pad have been suggested 21 , none of the studies we reviewed reported any noticeable side-effects or complications directly attributable to PRF application.
DISCUSSION
The use of RF electrical currents to create quantifiable and predictable thermal lesions has been practised since the 1950s 58 . The first reports of the use of any RF modality in the treatment of intractable pain were of CRF at neurodestructive temperatures for facet joint denervation, which appeared in the literature as early as 1975 59 . Several RCTs have since been published supporting the use of CRF at these temperatures in facet syndrome 60, 61 . The passage of RF currents through the RF electrode generated heat at the electrode tip and when placed in the vicinity of a sensory nerves or ganglia created a partial or a complete thermal lesion, in an attempt to interrupt the nociceptive signals. Temperatures above 45°C are known to be neurodestructive 57 and during CRF highest possible tissue temperatures without tissue gas formation were attained (80°C to 90°C). Although a selective action of the high temperature CRF lesions on unmyelinated C and A-delta fibres was initially suggested 62 , it was not substantiated by later studies which showed indiscriminate destruction of all nerve fibres 63 . Fear of motor deficits, neuritis and deafferentation pain with CRF at these neurodestructive temperatures restricted its use to facet denervation for some time.
To avoid thermal injury to the motor and large sensory nerve fibres, temperatures in the range of 55°C to 70°C were arbitrarily selected for lesioning of the DRGs in patients with radicular pain syndromes 64 . While investigating the efficacy of CRF for cervical DRG lesioning, Slappendel et al 65 arbitrarily used temperature of 40°C for their control group and noted no difference in the clinical outcomes between lesions made at 40°C or 67°C. The authors of this study theorised that it was either the current or the frequency of the impulses, rather than the temperature, that determined this clinical outcome. This observation generated intense interest among pain physicians, as it suggested that non-tissue-destructive RF temperatures could have the same clinical effects as tissue-destructive RF temperatures, thus significantly expanding the potential applications of RF and suggesting that factors other than temperature may be involved in the RF lesioning. The first study on PRF by Sluijter et al 8 noted the observation made in an earlier study 66 that CRF caused transient sensory loss but provided pain relief of much longer duration. They attributed this effect to factors other than temperature and suggested EMF as a possible alternative.
In an attempt to maximise the delivery of EMF while minimising the amount of heat generated, Sluijter et al 8 proposed pulsatile application of RF currents, allowing time for the heat to dissipate in between the RF pulses while using high voltages to maximise the delivery of EMF. To avoid thermal injury to the tissues a maximum average tissue temperature of 42°C was recommended. These authors further suggested that maintaining tissue temperatures below 42°C while applying CRF would require low voltages and would reduce the amount of EMF delivered, thus CRF at these temperatures would be ineffective. This hypothesis was supported by two clinical studies published simultaneously in the same paper, which showed that the clinical effects of PRF were superior to CRF at comparable temperatures (CRF at 42°C). They also claimed that the low temperatures generated by PRF were safe and none of the patients in these two studies showed any neurological sequelae.
The majority of the early clinical studies of PRF reported its clinical efficacy, however they consisted of case reports, retrospective studies and small un-controlled prospective trials. The almost uniform beneficial effects of PRF in these observational are difficult to ignore, however it is also possible that therapeutic failures with PRF were not reported, as studies with positive results are not only more likely to be written and submitted by the authors, they are also more readily accepted and published, creating a bias in favour of the reports with positive results 67 . The laboratory studies that followed, to explain the clinical benefits of PRF, yielded information that was at times inconsistent. The randomised, controlled clinical data available on PRF is limited to two recently published small sized trials reporting conflicting results 6,7 ; a level 3 (C) evidence; support by one RCT or inconsistent findings in multiple RCTs 68 .
CONCLUSION
Although the observational studies report the clinical efficacy of PRF, the controlled clinical data on pulsed radiofrequency is limited and provide a level-3 (C) evidence of its efficacy; support by one RCT or inconsistent findings in multiple RCTs. Despite the weakness of the controlled clinical data supporting its use, the apparent lack of side-effects and the wider applicability of PRF calls for further RCTs in order for the practising pain physician to clearly understand its role in the treatment of various chronic pain syndromes.
